Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future Directions
- 15 January 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (2) , 429-432
- https://doi.org/10.1158/0008-5472.can-06-2871
Abstract
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed. [Cancer Res 2007;67(2):429–32]Keywords
This publication has 22 references indexed in Scilit:
- A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate CancerMolecular Therapy, 2006
- Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma MultiformeMolecular Therapy, 2006
- Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activityGene Therapy, 2001
- THERAPEUTIC ROLE OF MEASLES VACCINE IN HODGKIN'S DISEASEThe Lancet, 1984
- REGRESSION OF HODGKIN'S DISEASE AFTER MEASLESThe Lancet, 1981
- Remission of chronic lymphocytic leukemia after smallpox vaccinationArchives of internal medicine (1960), 1978
- Immunotherapy of malignant melanoma with vaccinia virusArchives of Dermatology, 1974
- REGRESSION OF BURKITT'S LYMPHOMA IN ASSOCIATION WITH MEASLES INFECTIONThe Lancet, 1971
- POSSIBLE EFFECT OF MEASLES ON LEUKqMIAThe Lancet, 1971